Latest Chiasma Stories
NEW YORK and JERUSALEM, June 28 /PRNewswire/ -- Chiasma, Inc., a privately held biopharma company, announced that the Food and Drug Administration (FDA) has granted orphan drug designation for Chiasma's investigational new drug, Octreolin, an oral form of octreotide acetate that uses the Company's proprietary Transient Permeability Enhancer (TPE) technology for the oral treatment of acromegaly, a hormonal disorder that results from an excess of growth hormone. If a New Drug Application (NDA)...
JERUSALEM, Jan. 12 /PRNewswire/ -- Chiasma, Inc. today made the following announcements: Using the Company's proprietary Transient Permeability Enhancer (TPE) technology, scientists at Chiasma have delivered drugs orally in animal models that previously had only been available via injection.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.